R. Evans

The discovery of CCR3/H1 dual antagonists with reduced hERG risk.

B. Springthorpe, P. Barton, R. Riley, 2012, Bioorganic & medicinal chemistry letters.

The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors.

P. Raubo, P. Willis, R. Evans, 2020, Bioorganic & medicinal chemistry letters.

Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.

D. Kellerman, R. Evans, Dave Mathews, 2002, Advanced drug delivery reviews.

Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.

A. Davis, D. Ferguson, L. Kingston, 2006, Bioorganic & medicinal chemistry letters.